LunarCrush LLM | United Therapeutics, Corp. (UTHR)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[United Therapeutics, Corp.](/topic/united-therapeutics-corp)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"UBS reiterated $INSM at a Buy rating and a $XXX price target. $LQDA $UTHR UBS said: We see more upside to the Brinsupri story in NCFB following our KOL checks and survey results (n=29) with pulmonologists that manage 2.8K NCFB patients with confirmed diagnosis by CT scan. We are doing a KOL call on Brinsupri launch on 10/21 2pm ET. While our survey accounts for less than X% of NCFB patients with X exacerbations surveyed physicians noted XXX prescriptions written through September 2025. With the caveat that our physician checks indicate it can take 2-4 weeks for patients to initiate therapy"  
[X Link](https://x.com/Quantumup1/status/1980348113907830862) [@Quantumup1](/creator/x/Quantumup1) 2025-10-20T18:59Z 3849 followers, 2845 engagements


"$LQDA Looks like Judge Andrews calendar is free until the 29th of Oct. I expect we get a decision this week. Will be busy with the following catalysts. Oct 21st - Chest ASCENT Wk16 data Oct 28th - L606 R&D Day Oct 29th - $UTHR Earnings Nov 12th (est) - $LQDA Earnings"  
[X Link](https://x.com/mbamcnulty/status/1979815445772542402) [@mbamcnulty](/creator/x/mbamcnulty) 2025-10-19T07:42Z XX followers, 3428 engagements


"UBSthe PT on $INSM to $XXX from $XXX and reiterated at Buy after adding in additional Brinsupri indications to its model. $LQDA $UTHR UBS said that it expects rapid uptake of Brinsupri in non-cystic fibrosis bronchiectasis (NCFB) patientsINSM is well-positioned to execute on the launch as the sales force was deployed approximately XX months prior to launch engaging with physicians on disease education. UBS additionally said: We are raising our PT to $XXX (from $140) as we layer in additional Brinsupri indications in our model. INSM stock is up +136% YTD but we see more upside from here as -"  
[X Link](https://x.com/Quantumup1/status/1978096926642888783) [@Quantumup1](/creator/x/Quantumup1) 2025-10-14T13:53Z 3849 followers, 6315 engagements


"Some thoughts from ChatGPT on the XXX patent lawsuit between $LQDA & $UTHR"  
[X Link](https://x.com/paperhands91/status/1974529316890534169) [@paperhands91](/creator/x/paperhands91) 2025-10-04T17:37Z XXX followers, 3228 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

United Therapeutics, Corp.

Top Social Posts

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"UBS reiterated $INSM at a Buy rating and a $XXX price target. $LQDA $UTHR UBS said: We see more upside to the Brinsupri story in NCFB following our KOL checks and survey results (n=29) with pulmonologists that manage 2.8K NCFB patients with confirmed diagnosis by CT scan. We are doing a KOL call on Brinsupri launch on 10/21 2pm ET. While our survey accounts for less than X% of NCFB patients with X exacerbations surveyed physicians noted XXX prescriptions written through September 2025. With the caveat that our physician checks indicate it can take 2-4 weeks for patients to initiate therapy"
X Link @Quantumup1 2025-10-20T18:59Z 3849 followers, 2845 engagements

"$LQDA Looks like Judge Andrews calendar is free until the 29th of Oct. I expect we get a decision this week. Will be busy with the following catalysts. Oct 21st - Chest ASCENT Wk16 data Oct 28th - L606 R&D Day Oct 29th - $UTHR Earnings Nov 12th (est) - $LQDA Earnings"
X Link @mbamcnulty 2025-10-19T07:42Z XX followers, 3428 engagements

"UBSthe PT on $INSM to $XXX from $XXX and reiterated at Buy after adding in additional Brinsupri indications to its model. $LQDA $UTHR UBS said that it expects rapid uptake of Brinsupri in non-cystic fibrosis bronchiectasis (NCFB) patientsINSM is well-positioned to execute on the launch as the sales force was deployed approximately XX months prior to launch engaging with physicians on disease education. UBS additionally said: We are raising our PT to $XXX (from $140) as we layer in additional Brinsupri indications in our model. INSM stock is up +136% YTD but we see more upside from here as -"
X Link @Quantumup1 2025-10-14T13:53Z 3849 followers, 6315 engagements

"Some thoughts from ChatGPT on the XXX patent lawsuit between $LQDA & $UTHR"
X Link @paperhands91 2025-10-04T17:37Z XXX followers, 3228 engagements